Finally, PR that promotes the company. Biosante Pharmaceuticals Inc (NASDAQ:BPAX), declared enrollment of the first subject in the second legion of its worldwide Phase IIb clinical test to examine the safety and tolerability of Oxycyte® in patients with an acute, non-penetrating traumatic brain damage. www.crazyjoys.com/biotech-stocks-to-watch-inovio-pharmaceuticals-peregrine-pharmaceuticals-biosante-pharmaceuticals-synthetic-biologics-oxygen-biotherapeutics,20137587 PR